Atara Biotherapeutics (NASDAQ:ATRA) versus Opus Genetics (NASDAQ:IRD) Head to Head Survey

Opus Genetics (NASDAQ:IRD) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Opus Genetics and Atara Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	16	1	2.89
Atara Biotherapeutics	1	1	1	1	2.50

Opus Genetics currently has a consensus price target of $12.29, suggesting a potential upside of 180.50%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential downside of 2.56%. Given Opus Genetics’ stronger consensus rating and higher possible upside, research analysts clearly believe Opus Genetics is more favorable than Atara Biotherapeutics.

Earnings and Valuation

This table compares Opus Genetics and Atara Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	25.49	-$49.59 million	($1.35)	-3.24
Atara Biotherapeutics	$6.19 million	15.80	$32.69 million	($1.18)	-8.26

Atara Biotherapeutics has lower revenue, but higher earnings than Opus Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Opus Genetics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Profitability

This table compares Opus Genetics and Atara Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Atara Biotherapeutics	-269.42%	N/A	-73.01%

Summary

Opus Genetics beats Atara Biotherapeutics on 7 of the 13 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.